The pull factors are cost-effective trials, with data transfer to developed countries being legitimized by the World Trade Organization ( WTO), patient numbers, disease profile, and availability of highly adaptable internationally trained investigators who have no language barriers.
Because of the low incidence and prevalence of patients with FSGS, an efficient and productive study design that fosters collaboration is essential to implement cost-effective trials and to identify and recruit clinical subjects in a timely manner.
The process of screening and recruitment of participants to trials can then be significantly speeded up reducing the risk and cost to pharmaceutical companies, thereby leading to more efficient and cost-effective trials.
In this paper we described the design of a randomized cost-effective trial of the effect of Disease management on residents of homes for the elderly.
These results strongly suggest that the scheme has potential to be beneficial and cost effective and further trial(s) of such initiatives that include appropriate control groups would be warranted with an assessment of wider societal costs.
The present findings offer a promising complement to large-scale randomized trials where smaller trials may be informative and cost effective, particularly as a first run trial, when they incorporate multiple levels of the neurobiological mechanisms of brain and cognitive plasticity in well-defined populations.
However, there is currently insufficient evidence to definitively state whether or not remote cancer follow-up using technology is likely to be cost effective, since most existing randomised trial evidence relates to alternative models of follow-up using standard telephone calls only.
We used HOMA to assess insulin resistance and sensitivity as a cost effective method with validity for clinical trials.
Cost-effective clinical trials targeting genes, not tissues, and enrolling patients with different types of cancer could be supported by these organizations to accelerate the discovery of new cancer cures.
This strategy is essential if efficient and cost-effective clinical trials are to be conducted in the preclinical stage of Huntington's disease.
Thus, insights gleaned from "gene to function" studies could be translated into designing more efficient and cost-effective clinical trials for immune-targeted drug therapy in chronic inflammatory diseases.
